Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
8.85
+0.20 (2.31%)
Feb 19, 2026, 1:47 PM EST - Market open
Zevra Therapeutics Revenue
Zevra Therapeutics had revenue of $26.06M in the quarter ending September 30, 2025, with 605.36% growth. This brings the company's revenue in the last twelve months to $84.39M, up 244.60% year-over-year. In the year 2024, Zevra Therapeutics had annual revenue of $23.61M, down -14.02%.
Revenue (ttm)
$84.39M
Revenue Growth
+244.60%
P/S Ratio
5.77
Revenue / Employee
$1,430,305
Employees
59
Market Cap
498.23M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 23.61M | -3.85M | -14.02% |
| Dec 31, 2023 | 27.46M | 17.00M | 162.58% |
| Dec 31, 2022 | 10.46M | -18.19M | -63.50% |
| Dec 31, 2021 | 28.65M | 15.36M | 115.61% |
| Dec 31, 2020 | 13.29M | 449.00K | 3.50% |
| Dec 31, 2019 | 12.84M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Keros Therapeutics | 246.72M |
| Gossamer Bio | 44.05M |
| Prothena Corporation | 11.79M |
| Ocugen | 5.37M |
| 4D Molecular Therapeutics | 120.00K |
| Allogene Therapeutics | 22.00K |
| vTv Therapeutics | 17.00K |
ZVRA News
- 3 hours ago - Zevra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - Newsfile Corp
- 23 hours ago - Zevra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - Business Wire
- 15 days ago - Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA® in Patients with Neimann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium™ - GlobeNewsWire
- 17 days ago - Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026 - GlobeNewsWire
- 24 days ago - Zevra Therapeutics to Present Multiple Analyses on MIPLYFFA® at the 22nd Annual WORLDSymposium™ - GlobeNewsWire
- 4 weeks ago - Zevra Therapeutics, Inc. (ZVRA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 6 weeks ago - Zevra Therapeutics: Asymmetric Risk-Reward Setup In Ultra-Rare Disease Market - Seeking Alpha
- 2 months ago - Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire